Milurit (Allopurinol)

Allopurinol, the active ingredient in Milurit, is a xanthine oxidase inhibitor presented as an oral tablet for systemic use. It reduces uric acid production and is employed in the management of gout, hyperuricemia, and the prevention of tumor lysis syndrome in adult patients.

GNH USA supplies Milurit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets, offering consistent batch release, comprehensive documentation, and responsive technical support.

Allopurinol is indicated for conditions involving excess uric acid production and is used in the management of gout and related disorders. - Gout: lowers serum uric acid to prevent acute attacks and reduce tophi formation. - Hyperuricemia: maintains target uric acid levels to avoid crystal deposition. - Tumor lysis syndrome prophylaxis: reduces uric acid surge during chemotherapy‑induced cell breakdown.

Allopurinol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash: mild skin eruptions or itching. - Nausea: feeling of sickness often with or without vomiting. - Vomiting: expulsion of stomach contents. - Diarrhea: loose or watery stools. - Abdominal pain: discomfort in the stomach area. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin detachment and mucosal involvement. - Toxic epidermal necrolysis: life‑threatening skin loss. - Agranulocytosis: marked reduction in white blood cells. - Hepatitis: inflammation of the liver with possible jaundice. - Bone marrow suppression: pancytopenia or anemia. - Hypersensitivity syndrome: fever, rash, organ involvement.

When prescribing Allopurinol, clinicians should consider several safety measures to minimise risks. - Renal impairment: adjust dose and monitor renal function closely. - Gout flare: initiate therapy with anti‑inflammatory prophylaxis to avoid acute attacks. - Hypersensitivity: discontinue immediately if rash or systemic symptoms develop. - Pregnancy and lactation: use only if benefits outweigh potential risks, as data are limited. - Drug interactions: review concomitant medications for possible dose adjustments. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Allopurinol can alter the pharmacokinetics of several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Azathioprine: increased risk of bone marrow suppression. - Mercaptopurine: heightened toxicity and myelosuppression. - Theophylline: elevated plasma levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Thiazide diuretics: may reduce uric acid‑lowering efficacy. - ACE inhibitors: possible increase in serum creatinine, monitor renal function.